Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10
Submit an article Journal homepage
606
Views
41
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ertumaxomab: a trifunctional antibody for breast cancer treatment

Philipp Kiewe Charité Campus Benjamin Franklin, Department of Hematology and Oncology, Hindenburgdamm 30/31, D-12200 Berlin, Germany +49 30 84452337; +49 30 8445 4468; [email protected]
&
Eckhard Thiel Charité Campus Benjamin Franklin, Department of Hematology and Oncology, Hindenburgdamm 30/31, D-12200 Berlin, Germany +49 30 84452337; +49 30 8445 4468; [email protected]
Pages 1553-1558 | Published online: 22 Sep 2008

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Patrick M. Dillon, Jogender Tushir-Singh & Lawrence G. Lum. (2022) Bispecific antibodies for the treatment of breast cancer. Expert Opinion on Biological Therapy 22:8, pages 1017-1027.
Read now
Simone Diermeier-Daucher, Olaf Ortmann, Stefan Buchholz & Gero Brockhoff. (2012) Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. mAbs 4:5, pages 614-622.
Read now
Giampietro Gasparini & Raffaele Longo. (2012) The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets 16:sup1, pages S7-S16.
Read now
Jijie Gu & Tariq Ghayur. (2010) Rationale and development of multispecific antibody drugs. Expert Review of Clinical Pharmacology 3:4, pages 491-508.
Read now
Dimiter S. Dimitrov. (2010) Therapeutic antibodies, vaccines and antibodyomes. mAbs 2:3, pages 347-356.
Read now

Articles from other publishers (36)

Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe & Francesco Sabbatino. (2022) Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics 14:11, pages 2442.
Crossref
Alkhansa S. Mahmoud, Zuki AB. Zakaria, Hazilawati HJ. Hamzah & Tengku Ahbrizal F.T.A.. 2022. Breast Cancer: Current Trends in Molecular Research. Breast Cancer: Current Trends in Molecular Research 242 258 .
Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang & Huigen Feng. (2022) Cell Surface Markers and their Targeted Drugs in Breast Cancer. Current Protein & Peptide Science 23:5, pages 335-346.
Crossref
Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan & Xiaoming Xie. (2022) Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Cancer Control 29, pages 107327482210992.
Crossref
Yue Du & Jian Xu. (2021) Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials 33:48, pages 2103114.
Crossref
Mengjun Shu, Hongbin Yan, Chuanying Xu, Yan Wu, Zhaohua Chi, Weihong Nian, Zhuzi He, Jing Xiao, Hongli Wei, Qing Zhou & Joe X. Zhou. (2020) A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo. Scientific Reports 10:1.
Crossref
Jiani Wang & Binghe Xu. (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Strohl & Naso. (2019) Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies 8:3, pages 41.
Crossref
Sumayah Al-Mahmood, Justin Sapiezynski, Olga B. Garbuzenko & Tamara Minko. (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Delivery and Translational Research 8:5, pages 1483-1507.
Crossref
Amin RamezaniAbbas Ghaderi. (2018) Using a Dihydrofolate Reductase-Based Strategy for Producing the Biosimilar Version of Pertuzumab in CHO-S Cells. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 37:1, pages 26-37.
Crossref
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li & Kongming Wu. (2017) Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental Hematology & Oncology 6:1.
Crossref
Tessa G. Steenbruggen, Mette S. van Ramshorst, Marleen Kok, Sabine C. Linn, Carolien H. Smorenburg & Gabe S. Sonke. (2017) Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 77:12, pages 1313-1336.
Crossref
Mei Liu, Zhiyang Li, Jingjing Yang, Yanyun Jiang, Zhongsi Chen, Zeeshan Ali, Nongyue He & Zhifei Wang. (2016) Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Proliferation 49:4, pages 409-420.
Crossref
Andreas Baumann, Saileta Prabhu & Jitendra Kanodia. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 13 .
Tao Liu, Juanjuan Du, Xiaozhou Luo, Peter G Schultz & Feng Wang. (2015) Homogeneously modified immunoglobulin domains for therapeutic application. Current Opinion in Chemical Biology 28, pages 66-74.
Crossref
Qingzhong He, Haisong Zhang, Youzhao Wang, Hong Hoi Ting, Wenhua Yu, Xuetao Cao & Wei Ge. (2014) Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells. Cell & Bioscience 4:1.
Crossref
Ron D. Jachimowicz, Sven Borchmann & Achim Rothe. (2014) Multi-Specific Antibodies for Cancer Immunotherapy. BioDrugs 28:4, pages 331-343.
Crossref
Raymund Buhmann, Stanglmaier Michael, Hess Juergen, Lindhofer Horst, Christian Peschel & Hans-Jochem Kolb. (2013) Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. Journal of Translational Medicine 11:1.
Crossref
Helena Wållberg & Stefan Ståhl. (2013) Design and evaluation of radiolabeled tracers for tumor imaging. Biotechnology and Applied Biochemistry 60:4, pages 365-383.
Crossref
Leigh Ann Burns-Naas & Marc J. Pallardy. 2013. Nonclinical Safety Assessment. Nonclinical Safety Assessment 313 346 .
Dorte L. Nielsen, Iben Kümler, Jesper A.E. Palshof & Michael Andersson. (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. The Breast 22:1, pages 1-12.
Crossref
Philippe Fournier & Volker Schirrmacher. (2012) Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer. BioDrugs 27:1, pages 35-53.
Crossref
Fabrice Le Gall, Uwe Reusch, Anastasia Y. Bakulina & Sergej M. Kiprijanov. (2012) WITHDRAWN: Tetravalent Bispecific Single-Chain Fv Antibodies for Lysis of Leukemia Cells by Autologous T Cells. Journal of Molecular Biology.
Crossref
Mark J. Adler & Dimiter S. Dimitrov. (2012) Therapeutic Antibodies Against Cancer. Hematology/Oncology Clinics of North America 26:3, pages 447-481.
Crossref
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi & Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 9:1, pages 16-32.
Crossref
Dimiter S. Dimitrov. 2012. Therapeutic Proteins. Therapeutic Proteins 1 26 .
Sergej M. Kiprijanov. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology 441 482 .
Cinzia Azzoni, Lorena Bottarelli, Stefano Cecchini, Costanza Lagrasta, Silvia Pizzi, Tiziana D’Adda, Elisa Tamburini, Guido Rindi & Cesare Bordi. (2011) Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Archiv 458:5, pages 525-536.
Crossref
Eleri Davies & Stephen Hiscox. (2011) New therapeutic approaches in breast cancer. Maturitas 68:2, pages 121-128.
Crossref
Toru Mukohara. (2010) Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science 102:1, pages 1-8.
Crossref
Dafne Müller & Roland E. Kontermann. 2011. Antibody Expression and Production. Antibody Expression and Production 235 249 .
Ricardo H Álvarez. (2010) Present and future evolution of advanced breast cancer therapy. Breast Cancer Research 12:S2.
Crossref
Maha Zohra Ladjemi, William Jacot, Thierry Chardès, André Pèlegrin & Isabelle Navarro-Teulon. (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunology, Immunotherapy 59:9, pages 1295-1312.
Crossref
Dafne Müller & Roland E. Kontermann. (2010) Bispecific Antibodies for Cancer Immunotherapy. BioDrugs 24:2, pages 89-98.
Crossref
Jeffrey S. Ross, Elzbieta A. Slodkowska, W. Fraser Symmans, Lajos Pusztai, Peter M. Ravdin & Gabriel N. Hortobagyi. (2009) The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine. The Oncologist 14:4, pages 320-368.
Crossref
Nurit Hollander. (2009) Bispecific antibodies for cancer therapy. Immunotherapy 1:2, pages 211-222.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.